The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target upped by The Goldman Sachs Group from $29.00 to $33.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price suggests a potential downside of 4.29% from […]

Related Keywords

Canada ,United States ,James William Burns ,Zurcher Kantonalbank Zurich Cantonalbank ,Jacqualyna Fouse ,Goldman Sachs Group ,Agios Pharmaceuticals Inc ,Mirae Asset Global Investments Co ,Securities Exchange Commission ,Cantor Fitzgerald ,Agios Pharmaceuticals Price Performance ,Royal Bank ,News Ratings For Agios Pharmaceuticals Daily ,Jpmorgan Chase Co ,Institutional Trading Of Agios Pharmaceuticals ,Td Asset Management Inc ,Sg Americas Securities ,Agios Pharmaceuticals ,Get Free Report ,Exchange Commission ,Director Jacqualyn ,Kantonalbank Zurich Cantonalbank ,Asset Global Investments ,Management Inc ,Agios Pharmaceuticals Daily ,Nasdaq Agio ,Plagio ,Medical ,Boost Price Target ,The Goldman Sachs Group Inc ,